DiabetesMar 15, 2026
Bydureon (exenatide extended-release) can drop HbA1c by roughly 1.3 to 1.6 percentage points with a single weekly injection. That's a meaningful reduction for adults with type 2 diabetes who aren't getting enough from diet, exercise, and oral medications. But here's the tension worth understanding: head-to-head data show it's slightly less potent on both blood sugar and weight than liraglutide or semaglutide, two GLP-1 receptor agonists that now dominate the conversation.
So where does that leave Bydureon? Still effective, still convenient, but no longer the frontrunner. Whether it makes sense for you depends on what you're prioritizing and what trade-offs you're willing to accept.
DiabetesMar 15, 2026
A single patch the size of a postage stamp delivered semaglutide for an entire month in animal studies, mimicking four weekly injections from one 2×2 cm application. That is genuinely exciting. It is also, for now, entirely experimental. No GLP-1 patch is approved or commercially available for diabetes or obesity. Every current GLP-1 receptor agonist, including semaglutide, liraglutide, dulaglutide, and tirzepatide, reaches patients through injections or, in the case of oral semaglutide, a daily pill.
So if you have seen headlines about GLP-1 patches and wondered whether you should ask your doctor about one, the honest answer is: not yet. But the research pipeline is worth understanding, because it signals where treatment is headed.
Weight LossMar 15, 2026
Tirzepatide for weight loss isn't measured in "units" the way insulin is. It's prescribed in milligrams (mg), injected once a week, and follows a strict stepwise schedule. That milligram number turns out to be one of the strongest predictors of how much weight you'll lose: in the largest trial of non-diabetic adults with obesity, the difference between the lowest and highest maintenance doses was the difference between losing about 15% and nearly 21% of body weight over 72 weeks.
The dosing pattern across all major weight-loss trials is remarkably consistent. Start at 2.5 mg, climb slowly, settle into a maintenance dose of 5, 10, or 15 mg. Where you land on that ladder matters more than most people realize.
Weight LossMar 15, 2026
If you have obstructive sleep apnea (OSA) and you're carrying extra weight, you've probably heard the standard advice: lose weight and it'll get better. Easier said than done. So when a drug like Zepbound (tirzepatide) comes along and helps people lose significant weight, a natural question follows: could it actually improve your sleep apnea too?
The short answer is yes, it can make a meaningful difference. Multiple clinical analyses published in 2025 consistently show that GLP-1/GIP drugs like tirzepatide reduce the number of times your breathing stops or gets dangerously shallow each hour while you sleep. But before you start thinking you can toss your CPAP machine, there are some important caveats. This article breaks down how much improvement you can realistically expect and whether these medications could be right for your situation.
Weight LossMar 15, 2026
If you're considering prescription weight loss medication, you've probably heard of Zepbound and Wegovy. Both are weekly injections that produce significant weight loss, but one consistently outperforms the other on the scale. The tradeoff? The drug that helps you lose more weight doesn't yet have the same proof that it'll protect your heart.
Here's the bottom line from clinical trials: Zepbound typically produces about 5-7 percentage points more weight loss than Wegovy over a year to 18 months. But Wegovy has years of rigorous data showing it reduces heart attacks, strokes, and cardiovascular deaths. Zepbound's heart protection data is still being gathered, with major trial results expected soon.
Weight LossMar 13, 2026
Clinical evidence shows higher doses produce more weight loss, and the standard target of 2.4 mg per week exists for good reason. But the smartest strategy isn't simply "get to the top dose as fast as possible." It's a personalized approach that balances effectiveness, side effects, cost, and your long-term ability to stick with treatment. This article breaks down what the trials and real-world data actually show, so you can have a more informed conversation with your doctor.
GLP-1Mar 13, 2026
It is easy to understand the excitement. Weekly injections are effective but inconvenient. Oral formulations such as Rybelsus, which contains semaglutide, offer more comfort but still require careful dosing and often have gastrointestinal side effects. A GLP-1 patch could, in theory, offer steady absorption, fewer stomach problems, and far greater convenience. Unfortunately, the physics and biology of the skin make that dream extremely difficult to achieve.
GLP-1Mar 13, 2026
Several recent studies have asked whether GLP-1 receptor agonists, used for diabetes and weight loss, raise the risk of thyroid cancer. A few trials and one large French study report a small increase, while other large real world cohorts and drug specific reviews do not see a signal. For now, any absolute risk appears low, but people at higher baseline risk for thyroid cancer should be cautious and decisions should be individualized.
